» Articles » PMID: 2866963

Immediate Central and Regional Haemodynamic Effects of a New Beta 1-adrenergic Stimulating Drug, Xamoterol (Corwin) in Healthy Volunteers

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 2866963
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Dose-response curves for heart rate, arterial blood pressure, cardiac output, total peripheral resistance, systolic time intervals, forearm blood flow and forearm vascular resistance were obtained after i.v. administration of seven logarithmically increasing doses of xamoterol to 8 healthy volunteers. The total cumulative dose was 0.2 mg/kg b.w. At rest after the seventh dose of xamoterol heart rate, systolic blood, pressure, cardiac output and forearm blood flow were increased by 10%, 20%, 23% and 41%, respectively. Diastolic blood pressure was unchanged. Forearm vascular resistance was reduced by 21% and total peripheral resistance by 10%. Systolic time intervals were reduced: total electromechanical systole index (QS2I), left ventricular ejection time index (LVETI), pre ejection period index (PEPI) and PEP/LVET ratio by 4%, 2%, 12% and 14%, respectively. No side-effects were observed. During upright exercise after the seventh dose of xamoterol heart rate was reduced by 11% and systolic BP by 6%. Diastolic blood pressure was unchanged. Thus xamoterol increased the contractility of the heart with only a small increase in heart rate, increased systolic blood pressure and caused vasodilatation in resting skeletal muscle. During exercise the reduction in heart rate and blood pressure suggests beta-adrenoceptor blocking activity of the drug.

Citing Articles

Differential effects of beta-adrenoceptor partial agonists in patients with postural hypotension.

Mehlsen J, Stadeager C, TRAP-JENSEN J Eur J Clin Pharmacol. 1993; 44(1):7-11.

PMID: 8436159 DOI: 10.1007/BF00315272.


Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Ng H, Walley T, Tsao Y, Breckenridge A Eur J Clin Pharmacol. 1994; 46(4):361-5.

PMID: 7957523 DOI: 10.1007/BF00194406.


Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

FURLONG R, Brogden R Drugs. 1988; 36(4):455-74.

PMID: 2906865 DOI: 10.2165/00003495-198836040-00004.


Clinical pharmacology of epanolol. Pharmacodynamic aspects.

Harry J Drugs. 1989; 38 Suppl 2:18-27.

PMID: 2575976 DOI: 10.2165/00003495-198900382-00006.


Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?.

Waller D Br J Clin Pharmacol. 1990; 30(2):157-71.

PMID: 1976342 PMC: 1368213. DOI: 10.1111/j.1365-2125.1990.tb03760.x.

References
1.
Hallbook T, Mansson B, Nilsen R . A strain gauge plethysmograph with electrical calibration. Scand J Clin Lab Invest. 1970; 25(4):413-8. DOI: 10.3109/00365517009046221. View

2.
Svendsen T, Hartling O, TRAP-JENSEN J . Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers. Eur J Clin Pharmacol. 1980; 18(3):219-23. DOI: 10.1007/BF00563002. View

3.
DODGE H, Lord J, Sandler H . Cardiovascular effects of isoproterenol in normal subjects and subjects with congestive heart failure. Am Heart J. 1960; 60:94-105. DOI: 10.1016/0002-8703(60)90063-6. View

4.
Barlow J, Main B, Snow H . Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem. 1981; 24(3):315-22. DOI: 10.1021/jm00135a015. View

5.
WEISSLER A, Harris W, SCHOENFELD C . Bedside technics for the evaluation of ventricular function in man. Am J Cardiol. 1969; 23(4):577-83. DOI: 10.1016/0002-9149(69)90012-5. View